The Personalized Immunotherapy CIG, under the direction of Dr. Pramod Srivastava, was established in 2009. The Personalized Immunotherapy CIG has strong leadership from Angela Kueck, M.D., a medical oncologist at UConn Health and Ion Mandiou, Ph.D., an associate professor of computer science from the UConn School of Engineering. With a goal to understand the cellular and molecular mechanisms of immune responses against cancerous cells, the Personalized Immunotherapy CIG is at the forefront of developing novel cancer immunotherapy. Drs. Srivastava and Madiou have led the team using high throughput sequencing and bioinformatics tools to identify mutations in pre-clinical models (published in the Journal of Experimental Medicine 2014). This new therapy has recently been approved by the FDA as a Phase 1 trial for ovarian cancer.